On Tuesday, Developers of Russia’s Sputnik V coronavirus vaccine said that their vaccine is 95 percent effective against COVID-19 according to a second interim analysis of clinical trial data.
The calculations of its effectiveness were based on preliminary data obtained 42 days after the first dose, Russia’s health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said in a statement.
According to the statement, the vaccine had shown 91.4 percent effectiveness 28 days after the first dose, a figure based on 39 cases. Forty-two days later, after a second dose, data showed an efficacy of the vaccine above 95 percent.
In a statement Gamaleya’s director Alexander Gintsburg said: “The second analysis was conducted a week after volunteers got the second dose, meaning that their bodies have partially reacted to both doses.”
He said the centre expects the efficacy rate to be even higher three weeks after the second dose.
The statement said that 22,000 volunteers had been vaccinated with the first dose and more than 19,000 with both doses.
